{"schema_version":"secwatch.filing_event.v1","accession":"0001448431-26-000002","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.106170+00:00","generated_at":"2026-05-15T19:30:16.260611+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OptimizeRx Q4 net income $5.0M, record adj EBITDA $12.0M; guides FY2026 rev $109-114M","bullets":["Q4 revenue $32.2M (flat YoY); FY2025 revenue $109.4M (+19% YoY).","Q4 GAAP net income $5.0M ($0.26/diluted share) vs net loss $0.1M in Q4 2024.","Q4 adjusted EBITDA record $12.0M; FY2025 adj EBITDA $24.3M.","FY2026 guidance: revenue $109-114M, adjusted EBITDA $21-25M.","Board authorizes $10M share repurchase program effective Mar 12, 2026 through Mar 15, 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001448431-26-000002","json":"https://secwatch.observer/filing/0001448431-26-000002.json","markdown":"https://secwatch.observer/filing/0001448431-26-000002.md","text":"https://secwatch.observer/filing/0001448431-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/0001448431-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/oprx-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:30:16.260611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c73187658077e5f7c8c66c12f2f2dd98a609986","claim":"OptimizeRx Corp amended Amendment No. 4 (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, OptimizeRx Corporation (the “Company”) entered into Amendment No. 4 to the Financing Agreement (the “Amendment No. 4”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/0001448431-26-000002-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Effective","value":"2026-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}